Anemia  >>  Phase 1
Welcome,         Profile    Billing    Logout  

75 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Anemia
ACTRN12624000147583: A Therapeutic Equivalence Study comparing Iron (III) Hydroxide Polymaltose 100mg Hard Gelatin Capsules to Maltofer® 370 mg Tablets (100mg iron as iron polymaltose) in the treatment of Iron Deficiency Anaemia in Pregnant and Non-Pregnant Women, and Men

Not yet recruiting
1
240
 
AFT Pharmaceuticals Ltd, AFT Pharmaceuticals Ltd
Iron Deficiency Anaemia
 
 
ACTRN12615000056594: A Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AD-6626 in Normal, Healthy Volunteers and Subjects Heterozygous for the Aldehyde Dehydrogenase 2*1/*2 Genetic Variant With and Without Alcohol Administration

Recruiting
1
64
 
Nucleus Network, Aldea Pharmaceuticals
This study is for healthy volunteers. The intended use of the investigational product is the treatment of Fanconi Anemia
 
 
ACTRN12613000374763: A Phase 1 Single Blind, Randomized, Single-Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of ZY7318 (pegylated recombinant human erythropoietin) in Healthy Volunteers

Recruiting
1
32
 
Prolong Pharmaceuticals, LLC, Prolong Pharmaceuticals, LLC
Healthy volunteers study and investigational product would be targeted for secondary anemia due to renal cause.
 
 
ACTRN12614001240639: A study to determine the safety, tolerability and pharmacokinetics of ZYAN1 following oral administration in healthy volunteers.

Recruiting
1
100
 
Cadila Healthcare Limited , Cadila Healthcare Limited
Anemia , Hypoxia related disorders
 
 
ChiCTR-TRC-11001646: Comparative bioavailability of Ferrous Succinate Tablets Formulations

Completed
1
20
 
group1: 200-mg test (ferrous succinate, 100 mg*2, Hunan Huana Pharmaceutical Co., Ltd., China), group 2: 200-mg reference (Sulifei 100 mg*2, Nanjing Jinling Pharmaceutical Co. Ltd., Nanjing, China)
Beijing Hospital Clinical Trial Center; Hunan Huana Pharmaceutical Co., Ltd., China, Sponsored by Hunan Huana Pharmaceutical Co., Ltd.,China
Iron Deficiency Anemia
 
 
ChiCTR-EPC-15006638: A multicenter case-control study on aplastic anemia of multiple risk factors based on EDC data management platform

Recruiting
1
1000
 
no Intervention ;Nil
The First affiliated Hospital of Zhejiang Chinese Medical University; Zhejiang Province hospital of TCM, Zhejiang science and Technology Department
Aplastic anemia
 
 
ChiCTR-TRC-10000767: The Effect of Fortified Oat Milk Supplementation on Calcium, Iron and Vitamin A Status of Children Living in Rural Area

Completed
1
300
 
Every morning supplement oat drinks 200ml ;Maintain day-to-day diet, not to supplement oat drinks
Institute for Nutrition and Food Safety of Chinese Center for Disease Control; Sweden Oatly Company, Sweden Oatly Company
Bone mass decrease; Iron Deficiency Anemia immunity decrease
 
 
ChiCTR-RIC-17014222: Association between anemia and outcome in patients hospitalized for acute heart failure syndromes

Completed
1
3335
 
Nil
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College; Xuanwu Hosppital Capital Medical University, Capital Medical Development Research Fund
Acute heart failure
 
 
ChiCTR-TRC-11001741: Clinical trial of erythroid progenitor cell injection generated from cord blood to treat anemia after chemotherapy or radiotherapy of hematolgical maligance

Completed
1
244
 
transfusion of erythroid progenitor generated from cord blood + basal treatment ;basal treatment
Peking University People's Hospital; Ministry of Science and Technology, China, National High-tech R&D Program (863 Program)
hematolgical maligance
 
 
ChiCTR-ONRC-12003869: A single subcutaneous injection dose, dose-escalation phase I study on the tolerability and safety of recombinant erythropoiesis stimulating proteininjection ( CHO cell ) in patients with chronic kidney disease with anaemia

Completed
1
9
 
Single dose of study drug through subcutaneous infusion: 2.50μg/Kg ;Single dose of study drug through subcutaneous infusion: 3.00μg/Kg
Shanghai Changzheng Hospital; Level of the institution：, Shenyang Sunshine Pharmaceutical CO..LTD.
Chronic kidney disease with Anaemia
 
 
ChiCTR-ONRC-12003868: A mutiple -dose, dose-escalation phase I study on the tolerability and safety of recombinant erythropoiesis stimulating protein (CHO cell) injection in patients with chronic kidney disease with anemia

Completed
1
40
 
The dosage is 0.5 ug/Kg, subcutaneous injection, once a week, for 4 weeks ;The dosage is 1.0 ug/Kg, subcutaneous injection, once a week, for 4 weeks ;The dosage is 2.0 ug/Kg, subcutaneous injection, once a week, for 4 weeks ;The dosage is 0.5 ug/Kg, intravenous injection, once a week, for 4 weeks
Shengjing Hospital of China Medical University; Level of the institution：, Shenyang Sunshine Pharmaceutical CO..LTD.
Chronic kidney disease with anemia
 
 
NCT00960050: Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Active, not recruiting
1
173
US
polymorphism analysis, laboratory biomarker analysis, medical chart review, assessment of therapy complications
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Leukemia, Lymphoma, Methemoglobinemia, Nonmalignant Neoplasm
05/15
 
ChiCTR-IPR-14005720: A single center, Randomized controlled, opened clinical reserch for evaluating the effectiveness of recombinant human thrombopoietin combined with immunosuppressive therapy in the treatment of newly diagnosed acquired severe aplastic anemia

Recruiting
1
172
 
rTPO ;Ciclosporine
Blood Diseases Hospital, Chinese Academy of Medical Sciences; Level of the institution：, Nil
severe aplastic anemia
 
 
b-RBCs, NCT02757898: Transfusion of Biotinylated Red Blood Cells

Completed
1
5
US
Biotin-Labeled Red Blood Cells (RBCs)
Emory University, National Heart, Lung, and Blood Institute (NHLBI)
Anemia
11/18
11/18
ChiCTR1800019815: The important role of intravenous iron in perioperative period of abdominal surgery in children

Recruiting
1
268
 
Intravenous iron infusion ;Routine treatment
Children's Hospital of Chongqing Medical university; Children's Hospital of Chongqing Medical University, Medical Research Project of Chongqing Health and Family Planning Commission
iron-deficiency anemia
 
 
NCT04626414: Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers

Recruiting
1
32
US
Ferric maltol capsule, ST10, Feraccru, Accrufer, Ferric maltol suspension, ST10
Shield Therapeutics
Anemia, Iron Deficiency
11/20
11/20
NCT03814408: A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

Active, not recruiting
1
2
US
RP-L102
Rocket Pharmaceuticals Inc.
Fanconi Anemia Complementation Group A
12/20
03/22
NCT02101944: Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Checkmark From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Dec 2015 - Dec 2015: From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Completed
1
12
US
Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus
National Cancer Institute (NCI)
Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
05/21
05/24
ChiCTR2100048730: Intravenous iron sucrose and sequential oral nutritional butter treatment in Tibetan patients with iron deficiency anemia

Completed
1
50
 
iron fortified nutritional butter
Shigatse Municipal People’s Hospital; Shigatse Municipal People’s Hospital, Raise money independently
iron-deficiency anemia
 
 
NCT04775615: Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.

Not yet recruiting
1
36
NA
DDO-3055 tablets；Placebo
Jiangsu HengRui Medicine Co., Ltd.
Renal Anemia
05/21
06/21
NCT01720147: Quercetin in Children With Fanconi Anemia; a Pilot Study

Completed
1
30
US
Quercetin (dietary supplement)
Children's Hospital Medical Center, Cincinnati, Food and Drug Administration (FDA)
Fanconi Anemia
10/21
10/21
NCT04470063: Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Patients With Anemia of Non-dialysis Chronic Kidney Diseases.

Enrolling by invitation
1
30
RoW
DDO-3055 tablets, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Anemia Associated Chronic Kidney Disease
12/21
12/21
ChiCTR2100044895: A Study to Evaluate the Pharmacokinetics and Safety and Pharmacodynamics of Dedustat Tablets in Healthy Chinese Subjects

Recruiting
1
64
 
25mg dolustat tablets ;50mg dolustat tablets ;100mg dolustat tablets ;200mg dolustat tablets
Yiyang Central Hospital; Kangzhe (Hunan) Pharmaceutical Co., Ltd., Self-raised
Renal anemia
 
 
ToTem, NCT03836690: Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation

Recruiting
1
18
Europe
CD62L- Tem
University College, London, Medical Research Council
Lymphoma, Leukemia, Myeloma, Myelodysplastic Syndromes, Severe Aplastic Anemia, Primary Immune Deficiency, Graft Vs Host Disease
07/22
04/23
NCT05088655: A Bioequivalence Study of Hetrombopag in Healthy Subjects

Completed
1
58
RoW
Hetrombopag Olamine Tablet
Jiangsu HengRui Medicine Co., Ltd.
Sever Aplastic Anaemia
07/22
11/23
ChiCTR2200056404: Multicenter prospective observational study of the effects of calcitriol/parietal treatment on inflammatory status and anemia in Hemodialysis patients with SHPT in China

Recruiting
1
770
 
Oral calcitol ;I.v. Paricalcitol
The First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University, Self-funded
secondary hyperparathyroidism
 
 
HEC53856-RAD-103, NCT04925674: Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis.

Not yet recruiting
1
60
RoW
HEC53856
Sunshine Lake Pharma Co., Ltd., Nicoya Therapeutics (Shanghai) Co., Ltd.
Hemodialysis, Peritoneal Dialysis
09/22
01/23
NCT04439006: Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Completed
1
10
US
Best Practice, standard of care, standard therapy, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765
Jennifer Woyach, Janssen Scientific Affairs, LLC
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
09/22
09/22
ChiCTR2000040491: An open, dose-escalation phase I clinical study for evaluation of pharmacokinetic, pharmacodynamic, safety, tolerance of single and multiple oral administration of SAL-0951 tablets in healthy Chinese subjects

Not yet recruiting
1
36
 
SAL-0951 1mg ;SAL-0951 5mg ;SAL-0951 15mg
Peking University Third Hospital; Shenzhen Salubris Pharmaceuticals Co., Ltd, Sponsor
Renal anemia
 
 
CKD, NCT05636891: Pharmacokinetic/Pharmacodynamic Parameters of NNG-DEPO (Stimus) With Aranesp® (Amgen) in Treatment of Anemia in Patients on Dialysis

Active, not recruiting
1
43
RoW
Stimus
Nanogen Pharmaceutical Biotechnology Joint Stock Company, Vietstar Biomedical Research, Clinical Research Consultants, Inc., Clinical Research Viet Nam Skill Training And Consultant Company Limited
Chronic Kidney Disease
11/22
12/22
ACTRN12623000148673: Open-Label, Randomized, Fasted, Single Oral Dose, Crossover Trial to Assess the Relative Bioavailability of FP-045 and its Metabolite AD-835 After Single Doses of FP-045 2 X 75 mg Capsules (Test Drug) Compared to 150 mg Reconstituted FP-045 Drug Substance Liquid Formulation (Reference Drug) in Healthy Male Participants

Completed
1
8
 
Foresee Pharmaceuticals Co., Ltd., Foresee Pharmaceuticals Co., Ltd.
Fanconi anaemia
 
 
NCT04476277: Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

Completed
1
22
US
Biotin label
National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease, Sickle Cell Anemia
12/22
02/23
HEC53856-RAD-102, NCT04925661: HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia

Not yet recruiting
1
60
RoW
HEC53856, Roxadustat, Placebo
Sunshine Lake Pharma Co., Ltd., Nicoya Therapeutics (Shanghai) Co., Ltd.
Chronic Kidney Diseases, Renal Anemia
12/22
05/23
NCT04893187: A Phase 1 Study of SSS17 in Healthy Subjects.

Recruiting
1
76
RoW
SSS17, Placebo
Shenyang Sunshine Pharmaceutical Co., LTD., The Fifth Affiliated Hospital of Guangzhou Medical University
Anemia in Chronic Kidney Diseases
12/22
06/23
ChiCTR2200063239: A Randomized, Open-label, Two-dose, Single-dose, Two-cycle, Two-sequence Study to Evaluate Bioequivalence of Desidustat Tablets in Chinese Healthy Subjects in Fasting and Postprandial States

Not yet recruiting
1
54
 
Cycle 1: Test (T), Cycle 2: Reference (R, OxemiaTM) ;Cycle 1: Reference (R, OxemiaTM), Cycle 2: Test (T) ;Cycle 1: Test (T), Cycle 2: Reference (R, OxemiaTM) ;Cycle 1: Reference (R, OxemiaTM), Cycle 2: Test (T)
Wuhan Infectious Disease Hospital; Kangzhe (Hunan) Pharmaceutical Co., Ltd., Sponsor
Renal anemia
 
 
NCT03683810: The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia

Recruiting
1
50
RoW
Lactoferrin, Recombinant human erythropoietin
Cyprus University of Technology, Hematological Clinic - Nicosia General Hospital, German Oncology Center, Cyprus, Limassol Hematology-oncology Center
Anemia
01/23
06/23
NCT05657821: The Effect Of Pumpkin Seed Extract Capsules On Nutritional Status and Haemoglobin Level in Pregnant Women.

Recruiting
1
70
RoW
Pumpkin seeds extract capsules
Dr. Rosdiana Syakur, Hasanuddin University
Anemia During Pregnancy
01/23
08/23
NCT02960646: Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Completed
1
11
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Filgrastim, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Total-Body Irradiation, TBI, Total Body Irradiation, Whole Body Irradiation, Whole-Body Irradiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome
02/23
02/23
NCT02065596: Hematopoietic Stem Cell Transplant for Sickle Cell Disease

Completed
1
4
US
Fludarabine, Fludarabine monophosphate, Hematopoietic Stem Cell Transplant (HSCT)
Case Comprehensive Cancer Center
Sickle Cell Disease, Sickle Cell Anemia, SCD
02/23
02/23
NCT03926819: A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

Completed
1
20
US
HBI-002
Hillhurst Biopharmaceuticals, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Anemia, Sickle Cell
04/23
04/23
ChiCTR2200058594: A randomized controlled study of Rosallistat in the treatment of anemia in patients with multiple myeloma renal insufficiency

Recruiting
1
86
 
Roxadustat ;None
The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine, none
Multiple Myeloma
 
 
NCT05088733: Yang Yin Fu Zheng Jie Du Therapy in HBV Related Hepatocellular Carcinoma Induced Anemia (YYFZJDTIHBVRHCIA)

Recruiting
1
120
RoW
Yang Yin Fu Zheng Jie Du therapy, Routine medical care
Beijing Ditan Hospital
Hepatocellular Carcinoma
06/23
06/23
NCT04255875: Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Completed
1
52
US
Placebo, PF-07209326
Pfizer
Healthy, Sickle Cell Anemia
07/23
07/23
ChiCTR2300072489: A Single-Center, Open, Fixed-Sequence Phase I Clinical Study to Evaluate the Pharmacokinetic Effects of Multiple Doses of Desidustat Tablets on Single Dose of Bupropion Hydrochloride Sustained-Release Tablets in Healthy Subjects

Not yet recruiting
1
16
 
Desidustat tablets 150 mg, D4, D6, D8, D10, administered 4 times, Bupropion hydrochloride sustained-release tablets 150 mg, D1, D10, administered twice
Henan Privince Hospital of Traditional Chinese Medicine; Kangzhe (Hunan) Pharmaceutical Co., Ltd., Sponsor
Renal anemia
 
 
ChiCTR2300072490: A single-center, open, fixed-sequence phase I clinical study to evaluate the pharmacokinetics of multiple doses of Desidustat Tablets on a single dose of rosuvastatin calcium tablets in healthy subjects

Not yet recruiting
1
24
 
Desidustat tablets 150 mg, D4, D6, D8, D10, administered 4 times, Bupropion hydrochloride sustained-release tablets 150 mg, D1, D10, administered twice
Henan Privince Hospital of Traditional Chinese Medicine; Kangzhe (Hunan) Pharmaceutical Co., Ltd., Sponsor
Renal anemia
 
 
ChiCTR2300072509: A Single-Site, Randomized, Open-Label, Three-Cycle-Crossover Phase I Clinical Study to Evaluate the Pharmacokinetics of the Calcium-containing Phosphate Binder Calcium Acetate Tablets and the Non-calcium-containing Phosphate Binder Sevelamer Carbonate Tablets on Desidustat Tablets in Healthy Subjects

Not yet recruiting
1
24
 
Group 1: A-B-C A for Desidustat tablets 150 mg; B for Desidustat tablets150 mg + Sevelamer Carbonate tablets (2,400 mg, tid, 6 times in a row); C for Desidustat tablets150 mg + Calcium Acetate tablets (2001 mg, tid, 6 times in a row) ;Group 2: B-C-A A for Desidustat tablets 150 mg; B for Desidustat tablets 150 mg + Sevelamer Carbonate tablets (2,400 mg, tid, 6 times in a row); C for Desidustat tablets150 mg + Calcium Acetate tablets (2,001 mg, tid, 6 times in a row) ;Group 3: C-A-B A for Desidustat tablets 150 mg; B for Desidustat tablets150 mg + Sevelamer Carbonate tablets (2,400 mg, tid, 6 times in a row); C for Desidustat tablets150 mg + Calcium Acetate tablets (2,001 mg, tid, 6 times in a row) ;Group 4: A-C-B A for Desidustat tablets 150 mg; B for Desidustat tablets 150 mg + Sevelamer Carbonate tablets (2,400 mg, tid, 6 times in a row); C for Desidustat tablets150 mg + Calcium Acetate tablets (2,001 mg, tid, 6 times in a row) ;Group 5: B-A-C A for Desidustat tablets 150 mg; B for Desidustat tablets 150 mg + Sevelamer Carbonate tablets (2,400 mg, tid, 6 times in a row); C for Desidustat tablets150 mg + Calcium Acetate tablets (2,001 mg, tid, 6 times in a row) ;Group 6: C-B-A A for Desidustat tablets 150 mg; B for Desidustat tablets 150 mg + Sevelamer Carbonate tablets (2,400 mg, tid, 6 times in a row); C for Desidustat tablets150 mg + Calcium Acetate tablets (2,001 mg, tid, 6 times in a row)
He'nan Privince Hospital of Traditional Chinese Medicine; Kangzhe (Hu'nan) Pharmaceutical Co., Ltd., Sponsor
Renal anemia
 
 
NCT06080555: Bioequivalence Study of Ferric Carboxymaltose Injection in Participants With Iron Deficiency Anaemia

Completed
1
84
RoW
Ferric Carboxymaltose Injection, Ferric Carboxymaltose Injection [Ferinject]
Sichuan Huiyu Pharmaceutical Co., Ltd, The First Hospital of Jilin University, Suzhou Guochen Biotek Co., Ltd., Boji Data Technology (Beijing) Co., Ltd., Boji Medical Technology Co., Ltd.
Iron Deficiency, Anaemia
01/24
03/24
NCT06212154: CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Recruiting
1
13
RoW
ThisCART19A, Allogeneic CAR-T targeting CD19
Institute of Hematology & Blood Diseases Hospital, China, Suzhou Fundamenta Therapeutics
Autoimmune Hemolytic Anemia, CD19 CAR-T Cell Infusion
12/24
06/25
NCT05745883: Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants With CKD and Anemia

Recruiting
1
32
US
DISC-0974, Placebo
Disc Medicine, Inc
Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
09/24
05/25
NCT06231368: CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.

Recruiting
1
6
RoW
CNCT19 CAR-T cell therapy
Institute of Hematology & Blood Diseases Hospital, China, Juventas Cell Therapy Ltd.
Autoimmune Hemolytic Anemia, Autologous CD19 CAR-T, Failure of Three or More Lines of Therapy
01/25
08/25
NCT02986698: In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)

Enrolling by invitation
1
10
US
in utero hematopoietic stem cell transplantation
University of California, San Francisco, California Institute for Regenerative Medicine (CIRM)
Alpha Thalassemia Major, Hemoglobinopathy; With Thalassemia, Hemoglobinopathies, Fetal Anemia, Fetal Hydrops, Alpha; Thalassemia, Thalassemia Major, Thalassemia Alpha, A-Thalassemia
03/24
02/26
NCT04536792: A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Completed
1
122
Europe, US
AG-946, AG-946 Matched Placebo
Agios Pharmaceuticals, Inc.
Healthy Volunteers, Anemia, Sickle Cell
12/23
12/23
NCT06245746: UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Not yet recruiting
1
9
NA
umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)
Wuhan Union Hospital, China
Acute Myeloid Leukemia, Neutropenia, Anemia, Thrombocytopenia, Infections, Bleeding
12/24
12/25
NCT05676697: PI3K Delta Inhibitor in Relapsed / Refractory Autoimmune Hemolytic Anemia Patients After Receiving Two or More Lines of Therapy

Terminated
1
4
RoW
Linperlisib
Institute of Hematology & Blood Diseases Hospital, China, YL-Pharma
Autoimmune Hemolytic Anemia, Failure of Two Rounds of Treatment
01/24
02/24
NCT05904093: Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

Not yet recruiting
1
20
US
Fostamatinib
National Heart, Lung, and Blood Institute (NHLBI)
Sickle Cell Disease, Hb-SS Disease, Hemoglobin S, Disease Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin Beta Thalassemia Disease
08/24
05/26
NCT03531736: T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Active, not recruiting
1
17
US
Antithymocyte globulin (Rabbit), ATG, fludarabine, total body irradiation, TBI, cyclophosphamide, Rituxan, Allogeneic Hematopoietic Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Myeloid Diseases
05/25
05/25
NCT04478227: TPO-Mimetic Use in Children for Hematopoietic Failure

Active, not recruiting
1
15
US
Romiplostim, Nplate
Anjali Sharathkumar, Amgen
Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia, Refractory Cytopenia of Childhood, Myelodysplastic Syndrome(MDS)
01/24
06/24
NCT06398457: Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Not yet recruiting
1
8
NA
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score, JH-DSA Semi-Quant Screen Score, JH-DSA Semi-Quant Response Score
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Janssen Research & Development, LLC
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
06/26
12/26
ADAPT, NCT05662098: Alternative Dosing And Prevention of Transfusions

Recruiting
1
100
RoW
Hydroxyurea
Children's Hospital Medical Center, Cincinnati, Jinja Regional Referral Hospital (JRRH), Sickle Cell Clinic, Jinja, Uganda
Sickle Cell Disease
12/26
12/27
TIARA, NCT05386264: Autologous Tregs for Aplastic Anaemia

Recruiting
1
12
Europe
Expanded autologous T regulatory cells
King's College Hospital NHS Trust
Aplastic Anemia
09/24
04/25
NCT05263817: A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Recruiting
1
75
RoW
CD19/BCMA CAR T-cells, CD19/BCMA CAR T-cells injection
Zhejiang University, Yake Biotechnology Ltd.
POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis
10/24
10/24
NCT02928991: Fludarabine Based RIC for Bone Marrow Failure Syndromes

Recruiting
1
25
US
MRD-BMT with Fludarabine-based RIC for Acquired AA, MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia, MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
Children's Hospital of Philadelphia
Bone Marrow Failure Syndromes
02/25
12/26
DARA-AIHA, NCT05004259: The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia

Active, not recruiting
1
2
US
Daratumumab / Hyaluronidase Injection
Dartmouth-Hitchcock Medical Center
Hemolytic Anemia
12/24
12/25
NCT03249831: A Blood Stem Cell Transplant for Sickle Cell Disease

Active, not recruiting
1
3
US
Cyclophosphamide, Cytoxan, Pentostatin, NIPENT, Rabbit anti-thymocyte globulin, Rabbit ATG, Thymoglobulin, Tacrolimus, PROGRAF®, Mycophenolate mofetil, MMF, CellCept®, Myfortic, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant, CD4+ T-cell depleted HaploHCT, CD4+ T-cell depleted hematopoietic progenitor cell (HPC) product
City of Hope Medical Center, California Institute for Regenerative Medicine (CIRM)
Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell
11/24
11/24
ICONE, NCT05699005: Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO

Recruiting
1
238
Europe
Packed Red Blood Cells (PRBCs), ScVO2 assesment to guide transfusion
University Hospital, Lille, Amiens University Hospital, University Hospital, Caen, University Hospital, Rouen, Centre Hospitalier Universitaire Dijon, Centre hospitalier de Dunkerque, Centre Hospitalier de Lens
Cardiogenic Shock, Extracorporeal Membrane Oxygenation, Transfusion Related Complication, Anemia, Oxygen Delivery
09/25
12/25
NCT05660265: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

Recruiting
1
40
US
GSK4172239D, Placebo
GlaxoSmithKline
Hematologic Diseases, Anaemia, Sickle Cell
03/25
03/25
NCT05169580: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058

Recruiting
1
70
US
FTX-6058 oral capsule(s)
Fulcrum Therapeutics
Sickle Cell Disease, Sickle Cell Anemia
04/25
04/25
NCT03016806: Umbilical Cord Blood Transplantation From Unrelated Donors

Recruiting
1
30
US
Total Body Irradiation 1200 cGy, TBI 1200 cGy, Total Body Irradiation 200 cGy, TBI 200 cGy, Cyclophosphamide, Cy, Mesna, Pre-Mesna, Cord Blood Infusion, Busulfan, Bu, Fludarabine, Flu, Melphalan, Mel
University of Rochester
Acute Leukemia, Immune Deficiency Disorder, Congenital Hematological Disorder, Metabolism Disorder, Aplastic Anemia, Myelodysplastic Syndromes, Chronic Leukemia, Lymphoma, Multiple Myeloma, Solid Tumor
06/25
06/26
SMMART, NCT03878524: Serial Measurements of Molecular and Architectural Responses to Therapy () PRIME Trial

Terminated
1
2
US
Abemaciclib, LY-2835219, LY2835219, Verzenio, Abiraterone, CB 7598, Afatinib, BIBW 2992, BIBW2992, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Zirabev, Anti-VEGF Monoclonal Antibody SIBP04, SIBP 04, SIBP-04, SIBP04, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Biospecimen Collection, Biological Sample Collection, Specimen Collection, Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Cabazitaxel, Jevtana, RPR-116258A, Taxoid XRP6258, XRP-6258, Cabozantinib, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Celecoxib, Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-, Celebrex, SC-58635, YM 177, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, 934660-93-2, Copanlisib, BAY 80-6946, PI3K Inhibitor BAY 80-6946, Dabrafenib, BRAF Inhibitor GSK2118436, GSK-2118436, GSK-2118436A, GSK2118436, Dacomitinib, EGFR Inhibitor PF-00299804, PF-00299804, PF-00299804-03, PF-299804, Vizimpro, Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, Nubeqa, ODM 201, ODM-201, 1297538-32-9, Dasatinib, BMS-354825, Dasatinib Hydrate, Dasatinib Monohydrate, Sprycel, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, 1428935-60-7, Enasidenib, AG-221, CC-90007 Free Base, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Enzalutamide, ASP9785, MDV3100, Xtandi, Erlotinib, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Imatinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Leucovorin, Folinic acid, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, PF-06463922, Losartan, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Neratinib, (2E)-N-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide, HKI 272, HKI-272, PB 272, PB-272, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Panobinostat, Faridak, LBH589, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, HLX11, Ponatinib, AP-24534, AP24534, Quality-of-Life Assessment, Quality of Life Assessment, Regorafenib, BAY 73-4506, REGORAFENIB ANHYDROUS, Stivarga, Ruxolitinib, INCB-18424, INCB18424, Jakafi, Oral JAK Inhibitor INCB18424, Sirolimus, AY 22989, RAPA, Rapamune, Rapamycin, SILA 9268A, WY-090217, Sorafenib, BA4 43 9006, BAY 43-9006, Bay-439006, Sunitinib, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Tretinoin, 2,4,6,8-Nonatetraenoic acid, 3, 7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-E)-, Aberel, Airol, Aknoten, all trans-Retinoic acid, All-trans Retinoic Acid, All-trans Vitamin A Acid, all-trans-Retinoic acid, all-trans-Vitamin A acid, ATRA, Avita, beta-Retinoic Acid, Cordes Vas, Dermairol, Epi-Aberel, Eudyna, Renova, Retin-A, Retin-A MICRO, Retin-A-Micro, Retinoic Acid, Retisol-A, Ro 5488, Stieva-A, Stieva-A Forte, Trans Retinoic Acid, Trans Vitamin A Acid, trans-Retinoic Acid, Tretinoinum, Vesanoid, Vitamin A Acid, Vitamin A acid, all-trans-, Vitinoin, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449, Vorinostat, L-001079038, MSK-390, SAHA, Suberanilohydroxamic Acid, Suberoylanilide Hydroxamic Acid, Zolinza
OHSU Knight Cancer Institute, Oregon Health and Science University
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
12/20
12/20
NCT05773586: A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients

Recruiting
1
105
RoW
APG-5918, Placebo
Ascentage Pharma Group Inc.
Anemia
08/25
03/26
NCT05757310: A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

Recruiting
1
6
US
Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATS, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Pentostatin, (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7, 8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol, 2'-Deoxycoformycin, CI-825, Co-Vidarabine, Covidarabine, DCF, Deoxycoformycin, Nipent, PD-81565, Pentostatine, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia
10/26
10/26
NCT05832216: Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients With Aplastic Anemia

Recruiting
1
10
RoW
Daratumumab
Institute of Hematology & Blood Diseases Hospital
Aplastic Anemia, Platelet Transfusion Refractoriness
03/26
12/26
NCT06113302: A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Recruiting
1
40
US
Luspatercept, ACE-536
M.D. Anderson Cancer Center
Myelodysplastic Syndromes
06/26
06/26
NCT04802057: Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088

Active, not recruiting
1
9
Europe
SAR445088
Bioverativ, a Sanofi company
Autoimmune Haemolytic Anaemia
01/26
01/26
FANCA, NCT01331018: Gene Therapy for Fanconi Anemia

Terminated
1
3
US
Bone Marrow Aspiration, Filgrastim, FILGRASTIM, LICENSE HOLDER UNSPECIFIED, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tevagrastim, Genetically Engineered Hematopoietic Stem Progenitor Cells, Genetically Engineered HSPCs, Laboratory Biomarker Analysis, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone
Fred Hutchinson Cancer Center, National Heart, Lung, and Blood Institute (NHLBI), Rocket Pharma Limited
Fanconi Anemia
02/24
02/24

Download Options